Project Grant R21CA292179
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$421K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Cancer Institute awarded a $633,705 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic to investigate mechanisms underlying resistance to PARP inhibitor (PARPI) drugs in prostate cancer. The research aims to identify strategies to overcome PARPI resistance, which is a significant challenge in treating metastatic castrate-resistant prostate cancer (mCRPC). The award supports a 5-year project (12/11/2024 - 11/30/2029) focused on three key objectives: 1) examining...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to develop a novel gene therapy approach to target the oncogenic transcription factor HOXB13 and inhibit metastatic castration-resistant prostate cancer (mCRPC). The $636,289 award to Duke University, with sub-awards to the Medical College of Wisconsin and Icahn School of Medicine at Mount Sinai, aims to uncover the molecular mechanisms by which HOXB13 drives mCRPC...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $693,781 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at developing improved treatments for cancers with mutations in the IDH1 gene. The key objectives are to: Further understand how IDH1 inhibitor medicines work to slow cancer growth and why resistance ultimately develops, and...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $415,902 to the University of Massachusetts Boston to conduct research on overcoming therapy resistance in castration-resistant prostate cancer. The key objectives are to: Determine if expression of the transcription factor FOXA2 can drive prostate cancer cells into a multi-lineage transition state, enabling therapy resistance. Investigate how FOXA2 interacts with the AP-1...
The National Cancer Institute awarded Emory University a 5-year, $1,082,472 Project Grant (CFDA 93.395 - Cancer Treatment Research) to determine the molecular mechanisms underlying the transition of prostate adenocarcinoma to the lethal neuroendocrine prostate cancer subtype. The research aims to characterize how the transcription factor FOXA2 interacts with NKX2-1 to drive this transdifferentiation process, involving changes in DNA methylation, chromatin remodeling, and 3D genome...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to conduct research on leveraging reactive metabolite generation as a novel therapeutic strategy for patients with isocitrate dehydrogenase-mutant (IDHm) gliomas, a deadly form of brain cancer. The key objectives of this 5-year project are to: 1) determine if the combination of a brain-penetrant glyoxalase 1...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), supports a research project to investigate the impact of chromosomal instability on prostate cancer aggressiveness. The grant provides $1,456,062 in funding to the Mayo Clinic, a renowned non-profit academic medical center, over a five-year period from July 2024 to June 2029. The research project aims to mechanistically uncover novel aspects of...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $654,763 to The Johns Hopkins University to conduct research aimed at understanding how the gut microbiome promotes resistance to endocrine and immunotherapies in metastatic castration-resistant prostate cancer. The key products and services to be delivered include: Defining the functional significance of microbial-derived androgens on immunotherapy effectiveness, determining...
This $627,474 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at the Dana-Farber Cancer Institute (DFCI) to develop innovative epigenomic approaches for early detection and monitoring of neuroendocrine prostate cancer (NEPC) and enzalutamide resistance. The key objectives are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies to detect NEPC and predict enzalutamide...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $683,979.00 to the Weill Medical College of Cornell University to conduct research on the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The research aims to: Define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes of treatment-resistant castration-resistant prostate cancer (CRPC). Mechanistically...